Volume | 9,243 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Pacific Biosciences of California Inc | PACB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.60 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
57 | 9,243 | - | 1.25 - 14.55 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
04:08:57 | 87 | US$ 1.70 | USD |
Pacific Biosciences of California Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
428.72M | 267.95M | - | 200.52M | -306.74M | -1.14 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Pacific Biosciences of C... News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PACB Price Data
Period †| Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.56 | 1.70 | 1.30 | 1.45 | 9,474,176 | 0.12 | 7.69% |
1 Month | 3.60 | 3.70 | 1.25 | 1.93 | 12,683,791 | -1.92 | -53.33% |
3 Months | 6.42 | 6.83 | 1.25 | 3.58 | 9,925,978 | -4.74 | -73.83% |
6 Months | 7.22 | 10.65 | 1.25 | 5.43 | 8,290,904 | -5.54 | -76.73% |
1 Year | 10.58 | 14.55 | 1.25 | 7.23 | 6,087,392 | -8.90 | -84.12% |
3 Years | 30.32 | 36.36 | 1.25 | 9.64 | 5,088,984 | -28.64 | -94.46% |
5 Years | 7.40 | 53.69 | 1.25 | 11.37 | 4,115,763 | -5.72 | -77.30% |
Pacific Biosciences of C... Description
Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe. |